Clinical trials in Rotterdam – page 7

809 clinical trials in Rotterdam, The Netherlands across 7 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Rotterdam at a glance

809

clinical trials

Research sites7

Quick filters

809 trials in Rotterdam

Open in trial search

Triple negative breast cancer

Recruiting

Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

Registered drugNo placebo

Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Contact Research Centre

Bronchiectasis

Recruiting

A study to evaluate the safety and effectiveness of AZD0292 in people aged 12 years and older with bronchiectasis and chronic Pseudomonas aeruginosa infection

Investigational

A study to evaluate the safety and effectiveness of AZD0292 in people aged 12 years and older with bronchiectasis and chronic Pseudomonas aeruginosa infection

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:AZD0292
Sponsor:AstraZeneca AB

Contact Research Centre

Gastric cancer

Recruiting

A study of irinotecan and a drug combination for patients with gastric cancer or gastroesophageal junction cancer undergoing surgery.

Registered drugNo placebo

A study of irinotecan and a drug combination for patients with gastric cancer or gastroesophageal junction cancer undergoing surgery.

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Irinotecan Hydrochloride Trihydrate
Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Contact Research Centre

Interstitial lung disease+1

Recruiting

A study to evaluate the effectiveness of BI 1015550 in people with lung abnormalities and a family history of pulmonary fibrosis

Investigational

A study to evaluate the effectiveness of BI 1015550 in people with lung abnormalities and a family history of pulmonary fibrosis

Investigational

The Netherlands

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:BI 1015550
Sponsor:Boehringer Ingelheim International GmbH

Contact Research Centre

Autoimmune haemolytic anaemia+1

Recruiting

A study to evaluate the safety and effectiveness of tafasitamab in adults with autoimmune thrombocytopenia or autoimmune hemolytic anemia

Registered drugNo placebo

A study to evaluate the safety and effectiveness of tafasitamab in adults with autoimmune thrombocytopenia or autoimmune hemolytic anemia

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Tafasitamab
Sponsor:Incyte Corp.

Contact Research Centre

Propionic acidaemia

Recruiting

A study to evaluate the long-term safety and effectiveness of mRNA-3927 in patients with Propionic Acidemia

InvestigationalNo placebo

A study to evaluate the long-term safety and effectiveness of mRNA-3927 in patients with Propionic Acidemia

InvestigationalNo placebo

The Netherlands

Participants:0–17 years · 18–64 years
Substances:Modified Messenger Ribonucleic Acid Encoding Human Propionyl-Coenzyme A Carboxylase Alpha And Beta Subunits Encapsulated Into Lipid Nanoparticles
Sponsor:Moderna Inc.

Contact Research Centre

Metabolic dysfunction-associated liver disease

Recruiting

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:LY3437943 sodium
Sponsor:Eli Lilly & Co.

Contact Research Centre

Transitional cell carcinoma metastatic

Recruiting

Phase 1/2 Evaluation of Zilovertamab Vedotin in PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma

Registered drugNo placebo

Phase 1/2 Evaluation of Zilovertamab Vedotin in PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Interstitial lung disease

Recruiting

Efficacy and Safety of Subcutaneous Belimumab in Adults with Connective Tissue Disease-Associated Interstitial Lung Disease

Registered drug

Efficacy and Safety of Subcutaneous Belimumab in Adults with Connective Tissue Disease-Associated Interstitial Lung Disease

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Belimumab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Transitional cell carcinoma

Recruiting

A study of SKB410, enfortumab vedotin, and pembrolizumab combination for patients with locally advanced or metastatic urothelial cancer

Registered drugNo placebo

A study of SKB410, enfortumab vedotin, and pembrolizumab combination for patients with locally advanced or metastatic urothelial cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Gastrointestinal cancer metastatic

Recruiting

Study of GSK6042981 compared to sunitinib for patients with gastrointestinal stromal tumors that spread or cannot be removed after imatinib treatment

InvestigationalNo placebo

Study of GSK6042981 compared to sunitinib for patients with gastrointestinal stromal tumors that spread or cannot be removed after imatinib treatment

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Sunitinib
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Glycogen storage disease type II

Recruiting

A Study of S-606001 Added to Enzyme Replacement Therapy for Patients with Late-Onset Pompe Disease

Investigational

A Study of S-606001 Added to Enzyme Replacement Therapy for Patients with Late-Onset Pompe Disease

Investigational

The Netherlands

Participants:18–64 years
Sponsor:Shionogi B.V.

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Rotterdam

What the registry says about research in the country

01 Neurology and Mental Health

Innovative research focusing on frontotemporal dementia treatments and management of migraine in relation to obesity. Studies include evaluation of new therapeutic compounds and their effects on neurological conditions.

Dementia Treatment Studies
Migraine Management Research
Neurological Disease Interventions

Research aims to improve patient outcomes through targeted therapeutic approaches and innovative treatment methods.

02 Oncology and Cancer Research

Comprehensive studies targeting various forms of cancer, including advanced gastric cancer and bladder cancer. Research includes innovative imaging techniques and combination therapy approaches.

Gastric Cancer Treatment
Cancer Immunotherapy
Diagnostic Imaging Studies

Focus on developing more effective treatment strategies and improving diagnostic capabilities.

03 Metabolic and Endocrine Disorders

Clinical trials addressing obesity and related metabolic conditions, including innovative approaches to weight management and metabolic disease treatment. Studies evaluate new therapeutic options for thyroid disorders.

Weight Management Therapies
Thyroid Disease Treatment
Metabolic Disease Research

Research focuses on developing effective treatments for complex metabolic conditions.

Back to the Netherlands All countries